I'm LongbridgeAI, I can summarize articles.Fuan Pharmaceutical released its 2024 annual performance, with operating revenue of 2.391 billion yuan, a year-on-year decrease of 9.68%; net profit attributable to the parent company of 280 million yuan, a year-on-year increase of 20.69%; net profit excluding non-recurring gains and losses of 259 million yuan, a year-on-year increase of 1,467.78%; basic earnings per share of 0.24 yuan, and a proposed cash dividend of 0.5 yuan (tax included) for every 10 shares
According to the Zhitong Finance APP, Fuan Pharmaceutical (300194.SZ) released its 2024 annual report, stating that the company's operating income for 2024 is 2.391 billion yuan, a year-on-year decrease of 9.68%; the net profit attributable to shareholders of the listed company is 280 million yuan, a year-on-year increase of 20.69%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is 259 million yuan, a year-on-year increase of 1,467.78%; the basic earnings per share is 0.24 yuan/share. It plans to distribute a cash dividend of 0.5 yuan (including tax) for every 10 shares